Equities analysts predict that Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) will announce ($0.06) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Catalyst Pharmaceuticals’ earnings, with estimates ranging from ($0.06) to ($0.05). Catalyst Pharmaceuticals posted earnings of ($0.05) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 20%. The company is scheduled to announce its next earnings results on Wednesday, November 8th.

According to Zacks, analysts expect that Catalyst Pharmaceuticals will report full-year earnings of ($0.23) per share for the current fiscal year, with EPS estimates ranging from ($0.24) to ($0.22). For the next year, analysts expect that the business will post earnings of ($0.25) per share, with EPS estimates ranging from ($0.30) to ($0.14). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that follow Catalyst Pharmaceuticals.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01.

A number of brokerages have recently issued reports on CPRX. Piper Jaffray Companies set a $6.00 price target on shares of Catalyst Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, August 7th. SunTrust Banks, Inc. restated a “buy” rating and set a $5.00 price target on shares of Catalyst Pharmaceuticals in a report on Tuesday, September 5th. Roth Capital set a $5.00 price target on shares of Catalyst Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 10th. Finally, Zacks Investment Research downgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, July 12th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $4.90.

Catalyst Pharmaceuticals (CPRX) remained flat at $2.44 on Friday. 221,093 shares of the company traded hands. The stock has a 50 day moving average of $2.70 and a 200 day moving average of $2.29. Catalyst Pharmaceuticals has a 12-month low of $0.94 and a 12-month high of $3.20. The company’s market cap is $206.31 million.

In related news, insider Patrick J. Mcenany bought 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 5th. The stock was purchased at an average price of $2.58 per share, for a total transaction of $51,600.00. Following the acquisition, the insider now owns 4,471,026 shares of the company’s stock, valued at $11,535,247.08. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 8.79% of the stock is currently owned by company insiders.

Institutional investors have recently bought and sold shares of the stock. Nationwide Fund Advisors acquired a new stake in Catalyst Pharmaceuticals in the 2nd quarter valued at approximately $111,000. New York State Common Retirement Fund acquired a new stake in Catalyst Pharmaceuticals in the 2nd quarter valued at approximately $114,000. State of Wisconsin Investment Board acquired a new stake in Catalyst Pharmaceuticals in the 2nd quarter valued at approximately $149,000. Oxford Asset Management increased its holdings in Catalyst Pharmaceuticals by 138.1% in the 1st quarter. Oxford Asset Management now owns 58,940 shares of the biopharmaceutical company’s stock valued at $115,000 after purchasing an additional 34,181 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its holdings in Catalyst Pharmaceuticals by 1,861.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 63,114 shares of the biopharmaceutical company’s stock valued at $175,000 after purchasing an additional 59,896 shares during the last quarter. Hedge funds and other institutional investors own 40.15% of the company’s stock.

WARNING: This article was first published by Daily Political and is the property of of Daily Political. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/09/22/0-06-earnings-per-share-expected-for-catalyst-pharmaceuticals-inc-cprx-this-quarter.html.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.

Get a free copy of the Zacks research report on Catalyst Pharmaceuticals (CPRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.